CN101773179B - Health-caring tea for preventing cardiovascular and cerebrovascular diseases and preparation method thereof - Google Patents
Health-caring tea for preventing cardiovascular and cerebrovascular diseases and preparation method thereof Download PDFInfo
- Publication number
- CN101773179B CN101773179B CN2010101275959A CN201010127595A CN101773179B CN 101773179 B CN101773179 B CN 101773179B CN 2010101275959 A CN2010101275959 A CN 2010101275959A CN 201010127595 A CN201010127595 A CN 201010127595A CN 101773179 B CN101773179 B CN 101773179B
- Authority
- CN
- China
- Prior art keywords
- tea
- extract
- health
- pseudo
- ginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a health-caring tea for preventing cardiovascular and cerebrovascular diseases and a preparation method thereof. The ethanolic extract of ginkgo leaves is filtered and then processed by an anion-cation exchange resin column, so that ginkgo leaf extract is obtained. The ginkgo leaf extract and the ethanolic extract of pseudo-ginseng are dissolved in purified water and then sufficiently mixed with green tea leaves, the tea leaves are fermented according to the known Pu'er tea pile fermentation technique, and the fermented tea leaves are dried, so that the health-caring tea is obtained. By adopting a biological blending technique and utilizing tea leaf post-fermentation technique conditions, the ginkgo leaf extract, the pseudo-ginseng extract and the tea leaves are organically blended, the solubility and absorptivity of medicine are greatly increased, and thereby the health-caring effect is enhanced. The invention has the advantages of simple technique, high operability and moderate product price, and is suitable for industrialized production, and moreover, the health-caring tea can be taken by patients with cardiovascular and cerebrovascular diseases for a long time, and can be easily accepted by consumers.
Description
Technical field
The invention belongs to food processing technology field, be specifically related to a kind ofly can prevent health protection tea of cardiovascular and cerebrovascular disease and preparation method thereof.
Background technology
Along with people's growth in the living standard in recent years and aging population; The incidence of disease of cardiovascular and cerebrovascular disease is the trend that rises year by year; Cause very big life to threaten and stress to the patient; The patient needs to take medicine for a long time or all the life more simultaneously, and quality of life is had a strong impact on, and causes white elephant also for patient family and even entire society.At present, have much for this sick medicine, Western medicine prepn is mainly Statins and Bei Te class; Chinese medicine preparation mainly is some Chinese herbal medicines promoting blood circulation and removing blood stasis; Though have certain curative effect, majority is taken with the form of pharmaceutical preparation, causes the patient to be easy to generate psychological pressure.Tea-drinking is with its green that has; Natural and healthy drink the favor that advantage more and more receives the consumer; Since its unique production process with conveniently drink, and can reach the anxiety of releiving, prevention and health care, the purpose of raising quality of the life through drinking tea; Make the health tea-drinking more and more come into one's own, will become very important health-preserving beverage of 21st century.Though had medicinal herbs such as chrysanthemum, matrimony vine, gynostemma pentaphylla and tealeaves are carried out the assorted and herbal tea produced of physics; But it is flavour of a drug that the article drink gets up, and tea flavour is separated from each other, and has both lost the enjoyment of sampling tea; Also be difficult to experience the value of its health, therefore do not accepted always by popular.To this; With tealeaves is carrier; In conjunction with traditional Chinese medicine in the good result of treatment aspect the cardiovascular and cerebrovascular disease; Utilize biotechnology, develop generation and development that a tea-drinking with health care curative effect prevented and alleviated cardiovascular and cerebrovascular disease, alleviate important directions and emphasis that the misery of taking medicine for a long time and stress become research and development health care drink.
Summary of the invention
The objective of the invention is to deficiency to prior art; A kind of tealeaves after fermentation technology of utilizing is provided; Active ingredient and the tealeaves of ginkgo leaf and pseudo-ginseng are merged; Process have anti-anoxic, improve microcirculation, reducing blood lipid, help cardiovascular and cerebrovascular health, can prevent the health protection tea of cardiovascular and cerebrovascular disease.
Another object of the present invention is to provide a kind of method for preparing the health protection tea of this prevention cardiovascular and cerebrovascular disease.
The object of the invention is achieved through following technical scheme.
Except as otherwise noted, the percentage that the present invention adopted is percetage by weight.
A kind of health protection tea that prevents cardiovascular and cerebrovascular disease is processed by the raw material of following weight parts: 15～20 parts of crude green teas, 2～5 parts of 2～6 parts of ginkgo leaves and pseudo-ginseng.
Prepare the method for the health protection tea of above-mentioned prevention cardiovascular and cerebrovascular disease, comprise the steps:
1, take by weighing 15～20 parts of crude green teas, 2～5 parts of 2～6 parts of ginkgo leaves and pseudo-ginseng, subsequent use;
2, ginkgo leaf use concentration is 80%～90% alcohol extract, handles with the anion and cation exchange resin post behind the extracting liquid filtering, and will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use;
3, pseudo-ginseng use concentration is 80% alcohol extract, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use;
4, with ginkgo biloba p.e and Notogineng Extract with 5～20 parts of dissolved in purified water; Fully mix with solar dried green tea then; Ferment according to known Pu'er tea pile-fermentation technology afterwards, the tealeaves after the fermentation is through being drying to obtain the health protection tea of described prevention cardiovascular and cerebrovascular disease.
The present invention according in China tradition traditional Chinese medicine to the pathogenesis and the control principle of cardio-cerebralvascular diseases, with reference to modern medical theory, with strengthening vital QI to eliminate pathogenic factors; Blood-enrich; Legislation promoting blood circulation and removing blood stasis selects for use to have strengthening the spleen and replenishing qi, regulates negative and positive; Improve the natural Chinese medicinal herb of effects such as blood viscosity, according to the theory of traditional Chinese medical science prescription.Wherein, Ginkgo leaf is the leaf of ginkgo (Ginkgo biloba L); Experiment showed, that ginkgo biloba p.e has the effect of extremely strong anti-platelet activating factor, suppresses platelet aggregation, improves blood vessel tip and cerebrovascular circulation, antioxidation, can eliminate the interior superfluous various free radicals of organism, the effect that stops body lipid peroxidating, raising immunity of organisms, promotion to learn, improve memory, delay senility.Pseudo-ginseng (Panax notoginseng (Burk) F.H.Chen) has the characteristics of " stagnation resolvation is not just hindered ", has the tonifying Qi effect again simultaneously, and modern pharmacological research proves; Pseudo-ginseng has obvious coronary artery dilator, the cerebrovascular and peripheral vascular; Increase coronary flow and cerebral blood flow (CBF), improve the brain circulation, can also reduce MCO; Reduce myocardial contractive power; Strengthen anti-anoxic, the ischemic ability of heart and brain tissues, in addition, pseudo-ginseng also has reducing blood lipid, anti peroxidation of lipid, removing oxygen radical, suppresses platelet aggregation and thrombosis.
With ginkgo leaf, pseudo-ginseng and tealeaves compatibility, have promoting blood circulation and removing blood stasisly, improve hemorheology, the bidirectional modulation blood pressure, the effect of reducing blood lipid has prevention, treatment and back function of health care more to diseases of cardiovascular and cerebrovascular systems.
With respect to prior art, the present invention has the following advantages:
1, ginkgo biloba succi has been removed the undesirable substance ginkgoic acid that is contained in the ginkgo leaf through the processing of anion and cation exchange resin, has guaranteed the complete, effective of product.
2, this process using biotechnology has been utilized tealeaves after fermentation process conditions, and ginkgo biloba p.e, Notogineng Extract and tealeaves is organically fused, has significantly improved the dissolving and the absorptivity of medicine, thereby has strengthened the health care curative effect.
3, the sweat of Pu'er tea can produce statin substance, makes Pu'er tea itself just have the effect of control cardiovascular and cerebrovascular disease, adds the auxiliary of ginkgo leaf, Notogineng Extract, and effect will obviously strengthen.
4, the used production technology of the present invention is simple, workable, and the moderate product price of producing is fit to suitability for industrialized production.And meet the long-term prescription of cardiovascular and cerebrovascular disease, the consumer is acceptant.
5, the health protection tea of the prevention cardiovascular and cerebrovascular disease for preparing of the present invention confirms to have clear and definite health care curative effect through pharmacological research.
The specific embodiment
Through embodiment the present invention is done to specify further below, but they are not to qualification of the present invention.
Embodiment 1
Claim solar dried green tea 160kg, ginkgo leaf 20kg; Pseudo-ginseng 50kg; With the alcohol extract of ginkgo leaf with 80% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 50kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Fermented 45 days according to the Pu'er cooked tea production method of routine then, the tealeaves after the fermentation is through drying the health protection tea that promptly obtains described prevention cardiovascular and cerebrovascular disease.
Embodiment 2
Claim solar dried green tea 200kg, ginkgo leaf 60kg; Pseudo-ginseng 20kg. With the alcohol extract of ginkgo leaf with 90% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 200kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Fermented 50 days according to the Pu'er cooked tea production method of routine then, the tealeaves after the fermentation is through drying the health protection tea that promptly obtains described prevention cardiovascular and cerebrovascular disease.
Embodiment 3
Claim solar dried green tea 150kg, ginkgo leaf 50kg; Pseudo-ginseng 30kg; With the alcohol extract of ginkgo leaf with 85% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 100kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Fermented 40 days according to the Pu'er cooked tea production method of routine then, the tealeaves after the fermentation is through drying the health protection tea that promptly obtains described prevention cardiovascular and cerebrovascular disease.
Embodiment 4
Claim solar dried green tea 180kg, ginkgo leaf 40kg; Pseudo-ginseng 30kg; With the alcohol extract of ginkgo leaf with 90% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 80kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Fermented 45 days according to the Pu'er cooked tea production method of routine then, the tealeaves after the fermentation is through drying the health protection tea that promptly obtains described prevention cardiovascular and cerebrovascular disease.
Embodiment 5
Claim solar dried green tea 160kg, ginkgo leaf 20kg; Pseudo-ginseng 50kg; With the alcohol extract of ginkgo leaf with 80% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 50kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Then material is packed in the container, the heap height of material is 10cm, and then container being placed temperature is that 28 ℃, relative humidity are damp and hot fermentation 25 days under 40% the environment.The 3rd day with windrow stirring again but do not add pure water, whenever later at a distance from 3～5 days stirrings once presses 30% interpolation pure water of gross tea weight during each stirring, carries out 4 times stirring between yeast phase altogether; Tealeaves after the fermentation is through drying the health protection tea that promptly obtains required prevention cardiovascular and cerebrovascular disease.
Embodiment 6
Claim solar dried green tea 180kg, ginkgo leaf 40kg; Pseudo-ginseng 30kg; With the alcohol extract of ginkgo leaf with 80% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 150kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Then material is packed in the container, the heap height of material is 40cm, and then container being placed temperature is that 40 ℃, relative humidity are damp and hot fermentation 15 days under 80% the environment.The 2nd day with windrow stirring again but do not add pure water, whenever later at a distance from 3～5 days stirrings once presses 70% interpolation pure water of gross tea weight during each stirring, carries out 5 times stirring between yeast phase altogether; Tealeaves after the fermentation is through drying the health protection tea that promptly obtains required prevention cardiovascular and cerebrovascular disease.
Embodiment 7
Claim solar dried green tea 150kg, ginkgo leaf 50kg; Pseudo-ginseng 30kg; With the alcohol extract of ginkgo leaf with 90% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 80kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Then material is packed in the container, the heap height of material is 25cm, and then container being placed temperature is that 34 ℃, relative humidity are damp and hot fermentation 18 days under 60% the environment.The 3rd day with windrow stirring again but do not add pure water, whenever later at a distance from 3～5 days stirrings once presses 50% interpolation pure water of gross tea weight during each stirring, carries out 5 times stirring between yeast phase altogether; Tealeaves after the fermentation is through drying the health protection tea that promptly obtains required prevention cardiovascular and cerebrovascular disease.
Embodiment 8
Claim solar dried green tea 200kg, ginkgo leaf 50kg; Pseudo-ginseng 30kg; With the alcohol extract of ginkgo leaf with 90% concentration, directly handle behind the extracting liquid filtering with the anion-cation exchange resin post, will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use; Pseudo-ginseng is with the alcohol extract of 80% concentration, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use; The said extracted thing is dissolved in the 120kg pure water jointly, obtains mixed solution, and solution is fully mixed with solar dried green tea, soup is absorbed by crude green tea fully; Then material is packed in the container, the heap height of material is 25cm, and then container being placed temperature is that 34 ℃, relative humidity are damp and hot fermentation 18 days under 50% the environment.The 3rd day with windrow stirring again but do not add pure water, whenever later at a distance from 3～5 days stirrings once presses 40% interpolation pure water of gross tea weight during each stirring, carries out 5 times stirring between yeast phase altogether; Tealeaves after the fermentation is through drying the health protection tea that promptly obtains required prevention cardiovascular and cerebrovascular disease.
For the effect of the health protection tea of verifying prevention cardiovascular and cerebrovascular disease of the present invention, research below will experimentize to the influence that embodiment 4, embodiment 6 carry out anti-cerebral ischemia anoxic, antithrombotic formation, anti-arrhythmia and hyperlipemia.
One, to the influence of mouse brain hypoxic-ischemic
Experiment material and method
1. animal used as test SPF level ICR mouse, 4～6 ages in week, male and female half and half, 18～26g; Production licence is provided: SCXK (Yunnan) 2005-0008 by unming Medical College's Experimental Animal Center.Raise in the experimentation in the IVC laboratory.
2. experiment medicine 1#, 2# sample are the health protection tea of the prevention cardiovascular and cerebrovascular disease of embodiment 4 and embodiment 6, and method for distilling is identical; Folium Ginkgo, every contains general flavone glycoside 19.2mg, terpene lactone 4.8mg, Shenzhen Haiwang Pharmaceutical Co., Ltd, lot number: 20080207.
3. laboratory apparatus HS-4 thermostatic water-circulator bath, Chengdu Instruement Factory; The AL-204 electronic analytical balance, Mei Teletuo benefit instrument (Shanghai) Co., Ltd.; ELIXTM+Mlul-Qsynthesis ultra-pure water system, the U.S.: JJ2000 type electronic balance, the two outstanding tester in Changshu factory.
4. method 18～22g mouse is 72, and male and female half and half are divided into 6 groups at random by sex and body weight, see table 1.1#, 2# sample all adopt 1, two groups of dosage of 2g/kg (be equivalent to people's amount of drinking 5 times and 10 times), each 3 of Folium Ginkgo, and gastric infusion is 5 days continuously, and volume is 20ml/kg.30min after the last administration with mouse broken end fast behind ear, writes down holding time as the cerebral hypoxia ischemia time that each mouse dehisces to pant with scissors.
5. statistical method carries out data statistics with the SPSS11.0 statistical software, and measurement data is checked with T, and enumeration data adopts variance analysis, and heterogeneity of variance is used rank test.
Experimental result
Visible by table 1,1#, 2# sample with 1, the continuous gastric infusion of 2g/kg dosage 5 days, all there is obvious prolongation effect time of panting of dehiscing of broken end cerebral ischemia mouse.
The influence of table 1 pair decapitated mice acute cerebral ischemia
Compare with the blank group:
*P＜0.05,
*P＜0.01
Two, the influence of mouse thrombus in vivo formation
Experiment material and method
1. animal used as test SPF level ICR mouse, 4～6 ages in week, male and female half and half, 18～26g; Production licence is provided: SCXK (Yunnan) 2005-0008 by unming Medical College's Experimental Animal Center.Raise in the experimentation in I VC laboratory.
2. experiment medicine 1#, 2# sample are the health protection tea of the prevention cardiovascular and cerebrovascular disease of embodiment 4 and embodiment 6, and method for distilling is identical; Visit aspirin (ASP), the 100mg/ sheet, lot number BTA4RE2, BayerVital Gmby produces.
3. laboratory apparatus AL-204 electronic analytical balance, Mettler-Toledo Instrument (Shanghai) Co., Ltd.; ELIXTM+Mlul-Qsynthesis ultra-pure water system, the U.S.: JJ2000 type electronic balance, the two outstanding tester in Changshu factory.
4. method 18～22g mouse is 72, and male and female half and half are divided into groups and the administration situation is seen table 2.Successive administration 5 days, 30min after the last administration, the derivant that every mouse is processed by collagen-adrenaline by the dosage intravenous injection of 0.1ml/10g body weight is observed and record 15min interior each treated animal hemiplegia incidence and death rate.
5. statistical method carries out data statistics with the SPSS11.0 statistical software, and measurement data is checked with T, and enumeration data adopts variance analysis, and heterogeneity of variance is used rank test.
Experimental result
Visible by table 2, sample continuous irrigation stomach 5 days, the 1g/kg dosage that removes 1# is formed with obvious inhibitory action to collagen and adrenalin inducing mouse thrombus in vivo, and all the other samples are compared with the blank group only has effect trend.
The influence that table 2 pair mouse thrombus in vivo forms
Compare with the blank group:
*P＜0.05
Three pairs of chloroforms bring out the influence that mouse rhythm of the heart fibre quivers
Experiment material and method
1. animal used as test SPF level ICR mouse, 4～6 ages in week, male and female half and half, 18～26g; Production licence is provided: SCXK (Yunnan) 2005-0008 by unming Medical College's Experimental Animal Center.Raise in the experimentation in the IVC laboratory.
2. experiment medicine 1#, 2# sample are the health protection tea of the prevention cardiovascular and cerebrovascular disease of embodiment 4 and embodiment 6, and method for distilling is identical; Propranolol, 10mg/ sheet, Shantou metal and stone pharmacy head factory, lot number: 051002.
3. laboratory apparatus AL-204 electronic analytical balance, Mettler-Toledo Instrument (Shanghai) Co., Ltd.; ELIXTM+Mlul-Qsynthesis ultra-pure water system, the U.S.: JJ2000 type electronic balance, the two outstanding tester in Changshu factory.
4. method 24～26g mouse is 72, and male and female half and half are divided into groups and table 3 is seen in administration.30min after the administration puts into the glass beaker of 500ml back-off one by one with mouse, the built-in cotton balls (later every animal is injected chloroform 0.5ml) that contains the 2ml chloroform, treat that animal breath stops after, cut open chest immediately, observe the ventricular fibrillation incidence that mouse respectively organized in record also.
5. statistical method carries out data statistics with the SPSS11.0 statistical software, and measurement data is checked with T, and enumeration data adopts variance analysis, and heterogeneity of variance is used rank test.
The result
Visible by table 3,1#, 2# sample with 1, the continuous gastric infusion of 2g/kg dosage five days, each group is all brought out the mouse arrhythmia cordis to chloroform has obvious antagonism.
Table 3 pair chloroform brings out the influence of mouse ventricular fibrillation
Compare with blank:
*P＜0.05,
*P＜0.01
The influence of four pairs of hyperlipemia in mice blood lipid levels
Experiment material and method
1. animal used as test SPF level ICR mouse, 4～6 ages in week, male and female half and half, 18～26g; Production licence is provided: SCXK (Yunnan) 2005-0008 by unming Medical College's Experimental Animal Center.Raise in the experimentation in the IVC laboratory.
2. experiment medicine 1#, 2# sample are the health protection tea of the prevention cardiovascular and cerebrovascular disease of embodiment 4 and embodiment 6, and method for distilling is identical; Fenofibrate, 0.1g/ sheet, Yixing, Jiangsu pharmaceutical factory that advances, lot number 050220; Notoginsenoside, Yunnan Yunke Pharmaceuticals Co., Ltd., lot number 070109; 20070804), TG (lot number: 20070724), HDL-C (lot number: 20070311) kit, Shanghai Kehua Dongling Diagnosis Products Co., Ltd. TC (lot number:; LDL-C (lot number: 711125021) kit, Beijing Leadman Biochemistry Technology Co., Ltd.; Glucose, analyze pure, the Tianjin north day medical chemistry chemical reagent work, lot number 20080324; The concentrated sulfuric acid is analyzed purely, and Tianjin causes chemical reagent far away Co., Ltd, lot number 20080315; Trichloroacetic acid, analyze pure, last seamount Pu chemical industry Co., Ltd, lot number 20071110; Anthrone, analyze pure, China Medicine (Group) Shanghai Chemical Reagent Co.,, lot number 001116; Thiocarbamide, analyze pure, the rich chemical industry far away in Tianjin Co., Ltd, lot number 20020227; Sodium chloride for injection, 500ml/ bottle, Kuming Nanjiang Pharmacy Co., Ltd, lot number B061102d.
3. laboratory apparatus AL-204 electronic analytical balance, Mettler-Toledo Instrument (Shanghai) Co., Ltd.; ELIXTM+Mlul-Qsynthesis ultra-pure water system, the U.S.: JJ2000 type electronic balance, the two outstanding tester in Changshu factory.
4. method is selected 108 of 18～22g mouse for use, and male and female half and half are divided into 9 groups by body weight and sex: the normal control group at random; Model group; Fenofibrate 100mg/kg group; 1#, 2# establish basic, normal, high dose groups for the health protection tea of prevention cardiovascular and cerebrovascular disease; Every group 12.Except that the normal control group was fed normal diet, all the other each treated animals were all fed high lipid food, freely ingested and drank water.Each treated animal is according to dosage irritated stomach to being tried thing once every day during the moulding, and volume is 20ml/kg, and blank group and model group are irritated the isometric pure water of clothes, continuous 14 days.Water 12h is can't help in fasting after the last administration, gets blood by eye socket, and separation of serum is pressed the content that kit method is measured TC, TG, HDL-C, LDL-C.
High lipid food prescription: 1% cholesterol, 10% lard, 0.5% sodium taurocholate, 5% sucrose, 0.2% propylthiouracil, 83.3% basal feed.Behind hot lard dissolving cholesterol, each thing mixing adds water and stirs, and the kneading frustillatum is inserted in 80～100 ℃ of baking ovens and dried.
5. statistical method carries out data statistics with the SPSS11.0 statistical software, and measurement data is checked with T, and enumeration data adopts variance analysis, and heterogeneity of variance is used rank test.
The result
Can be known by table 4: the blood lipid level of model control group animal shows the modeling success apparently higher than the blank group.Under the high fat diet condition, the health protection tea of 1#, 2# prevention cardiovascular and cerebrovascular disease can suppress the rising of high fat diet mice serum TG, T C, LDL-C level effectively, stops the reduction of HDL-C level.Effect with auxiliary antilipemic is described.
Each group of table 4 is to the influence of hyperlipemia in mice blood lipid level
Compare with blank:
△P＜0.05,
△ △P＜0.01; Compare with the model contrast:
*P＜0.05,
*P＜0.01
Conclusion: the experimental study that is brought out mouse arrhythmia cordis and hyperlipemia blood fat water by thrombosis, chloroform in mouse brain hypoxic-ischemic, the collagen and adrenalin inductor is visible; 1#, 2# sample can prolong dehiscing the time of panting of broken end cerebral ischemia mouse; Suppress collagen and adrenalin inducing mouse thrombus in vivo and form, the antagonism chloroform brings out the effect of mouse arrhythmia cordis and reducing blood lipid.Explain that the health protection tea of prevention cardiovascular and cerebrovascular disease of the present invention has the effect of prevention cardiovascular and cerebrovascular disease.
Claims (1)
1. health protection tea that prevents cardiovascular and cerebrovascular disease, process by the method for following step:
(1) take by weighing 15～20 parts of crude green teas, 2～5 parts of 2～6 parts of ginkgo leaves and pseudo-ginseng, subsequent use;
(2) ginkgo leaf use concentration is 80%～90% alcohol extract, handles with the anion and cation exchange resin post behind the extracting liquid filtering, and will be concentrated into relative density through the ethanol extract of resin column is 1.20 ± 0.05, obtains ginkgo biloba p.e, subsequent use;
(3) pseudo-ginseng use concentration is 80% alcohol extract, and it is 1.20 ± 0.05 that extract is concentrated into relative density, obtains Notogineng Extract, subsequent use;
(4) with ginkgo biloba p.e and Notogineng Extract with 5～20 parts of dissolved in purified water; Fully mix with solar dried green tea then; Ferment according to known Pu'er tea pile-fermentation technology afterwards, the tealeaves after the fermentation is through being drying to obtain the health protection tea of described prevention cardiovascular and cerebrovascular disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101275959A CN101773179B (en) | 2010-03-19 | 2010-03-19 | Health-caring tea for preventing cardiovascular and cerebrovascular diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101275959A CN101773179B (en) | 2010-03-19 | 2010-03-19 | Health-caring tea for preventing cardiovascular and cerebrovascular diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101773179A CN101773179A (en) | 2010-07-14 |
| CN101773179B true CN101773179B (en) | 2012-07-18 |
Family
ID=42509870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101275959A Expired - Fee Related CN101773179B (en) | 2010-03-19 | 2010-03-19 | Health-caring tea for preventing cardiovascular and cerebrovascular diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101773179B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813683B (en) * | 2011-06-09 | 2013-12-04 | 北京华夏众芳生物科技有限公司 | Gingko leaf extract capable of delaying senescence and preparation method and application thereof |
| CN116570653B (en) * | 2023-04-24 | 2023-10-10 | 遵义市中医院 | Alcohol extraction fermentation process of lipid-lowering traditional Chinese medicine composition and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1129118A (en) * | 1995-02-15 | 1996-08-21 | 昆明制药股份有限公司 | Compounded preparation of notoginseng |
| CN1555875A (en) * | 2004-01-12 | 2004-12-22 | 黄巧玲 | Notoginseng ginkgo health care food and its preparation method |
| CN1679703A (en) * | 2005-01-28 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Medicinal preparation containing notoginseng and ginkgo leaf for cardio-cerebral blood vessel diseases and its preparing method |
| CN1843205A (en) * | 2006-05-12 | 2006-10-11 | 庞会心 | Preparation process of health food for preventing and treating cardiovascular and cerebrovascular disease |
| CN101107955A (en) * | 2007-08-24 | 2008-01-23 | 游文龙 | Health-care puer ripe tea and preparing method thereof |
-
2010
- 2010-03-19 CN CN2010101275959A patent/CN101773179B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1129118A (en) * | 1995-02-15 | 1996-08-21 | 昆明制药股份有限公司 | Compounded preparation of notoginseng |
| CN1555875A (en) * | 2004-01-12 | 2004-12-22 | 黄巧玲 | Notoginseng ginkgo health care food and its preparation method |
| CN1679703A (en) * | 2005-01-28 | 2005-10-12 | 北京阜康仁生物制药科技有限公司 | Medicinal preparation containing notoginseng and ginkgo leaf for cardio-cerebral blood vessel diseases and its preparing method |
| CN1843205A (en) * | 2006-05-12 | 2006-10-11 | 庞会心 | Preparation process of health food for preventing and treating cardiovascular and cerebrovascular disease |
| CN101107955A (en) * | 2007-08-24 | 2008-01-23 | 游文龙 | Health-care puer ripe tea and preparing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101773179A (en) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102634441B (en) | A kind of preparation method of health-care vinegar | |
| CN103610718B (en) | A kind of plant section containing total secondary ginseng glucoside and preparation thereof | |
| CN102178756A (en) | Oral liquid for treating high altitude disease (HAD) and preparation method thereof | |
| CN103585400B (en) | Have and strengthen immunologic function and the compositions alleviating fatigue effect and preparation method thereof | |
| CN102652801A (en) | Chinese herbal medicine tea bag for lowering blood sugar and preventing diabetes mellitus complications | |
| CN107400608A (en) | A kind of Sang Ju Yin wine and preparation method thereof | |
| CN101810657B (en) | American ginseng contained composition and American ginseng tea drink | |
| CN101791024A (en) | Diet tea and preparation method thereof | |
| CN104667197A (en) | Composition for strengthening immunity and preparation method and application of composition | |
| CN101773179B (en) | Health-caring tea for preventing cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN104027494A (en) | Traditional Chinese medicinal composition with effects of delaying senescence and protecting health | |
| CN109628265A (en) | A kind of liver-protection health-care molecule wine and preparation method thereof containing general flavone | |
| CN101911988A (en) | Bamboo leaf health-care tea and preparation method thereof | |
| CN102823862A (en) | Composition for qi-insufficiency constitution as well as preparation method and purpose of composition | |
| CN107648287B (en) | Young chicken paste ointment and application thereof in preparation of medicine for treating cracked nipple of lying-in woman | |
| CN104371894A (en) | Chrysanthemum flower eyesight-improving traditional Chinese medicine wine and preparation method thereof | |
| CN103859515A (en) | Composite kudzu root and cherry drink and preparation method thereof | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN101204438B (en) | Application of potentilla anseriana extractive on preparating anti-ischemic | |
| CN104147072A (en) | Methods for preparing roasted epimedium and medicinal liquor of roasted epimedium | |
| CN101129604B (en) | Antihypelipidemic traditional Chinese medicine producing method | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN102488063A (en) | Health preserving jujube containing Saussurea involucrata and preparation method thereof | |
| CN104099214B (en) | A kind of papaya wine with health care | |
| CN107773621B (en) | Health food composition for enhancing immunity and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 Termination date: 20130319 |